MedPath

Dronabinol On the Pain Experience

Phase 4
Terminated
Conditions
Trauma Injury
Interventions
Drug: Standard of Care (acetaminophen +naproxen +gabapentin + as needed oxycodone or Tramadol)
Registration Number
NCT05820685
Lead Sponsor
The University of Texas Health Science Center, Houston
Brief Summary

The purpose of this study is to identify the effect dronabinol has on opioid exposure when used as an adjunct to the current standard multi-modal pain regimen (MMPR)

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
484
Inclusion Criteria
  • patients admitted to the floor, Surgical Intermediate Medical Unit (SIMU), Shock-Trauma ICU (STICU) at Memorial Herman Hospital-Texas Medical Center(MHH-TMC)
Exclusion Criteria
  • Pregnant
  • Prisoner
  • Patients placed in observation unit
  • Non-acute trauma
  • Admitted with primary burn injury
  • Expired prior to admission
  • Moribund
  • Discharge from emergency department
  • Left against medical advice

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Standard of CareStandard of Care (acetaminophen +naproxen +gabapentin + as needed oxycodone or Tramadol)-
Standard of Care + DronabinolDronabinol-
Standard of Care + DronabinolStandard of Care (acetaminophen +naproxen +gabapentin + as needed oxycodone or Tramadol)-
Primary Outcome Measures
NameTimeMethod
Total Morphine Milligram Equivalents (MME) Per DayFrom time of admission to time of discharge (about 11 days after admission)

This will be calculated by calculated by taking the total of MMEs from all opioids received and dividing by length of stay

Secondary Outcome Measures
NameTimeMethod
Pain as Assessed by the Defense and Veterans Pain Rating Scale (DVPRS)From time of admission to time of discharge (about 11 days after admission)

This is a 4 item questionnaire and each is scored from 0(no pain) to 10( as bad as it could be, nothing else matters), enhanced with functional word descriptor anchors at each pain level and "traffic light" color coded bars to delineate levels of pain; mild (1 to 4, green), moderate (5 to 6, yellow), and severe (7 to 10, red) pain a higher number indicating more pain Average pain score during the course of the hospital stay will be reported.

Number of Hospital Free Days30 days

This will be calculated as (30 days-length of stay (LOS))

ICU Length of Stay (Participants With >0 ICU Days)From time of admission to ICU to time of discharge from ICU (about 12 days after admission)
Number of Days on a Ventilator (Participants With > 0 Days on a Ventilator)From time of intubation to time of extubation (about 14 days after admission)
Number of ICU Free Days (Participants With >0 ICU Days)30 days

This will be calculated as (30 days-number of days in ICU)

Number of Ventilator Free Days (Participants With >0 Days on a Ventilator)30 days

This will be calculated as (30 days-number of days spent on ventilator)

Total Morphine Milligram Equivalents (MME) Over Hospital StayFrom time of admission to time of discharge (about 11 days after admission)

This will be calculated by calculated by taking the total of MMEs from all opioids received

Number of Participants Discharged Form Hospital Without a Prescription for an Opioid MedicationDischarge (about 11 days after admission)
Number of Participants Discharged Form Hospital With a Prescription for an Opioid MedicationDischarge (about 11 days after admission)
Number of Participants That Have Incidences of Opioid-related Complications, Such as Ileus, Aspiration, Unplanned Intubation, Unplanned Admission to an Intensive Care Unit, and Use of an Opioid-reversal Agent.From time of admission to time of discharge (about 11 days after admission)
Hospital Length of StayFrom time of admission to time of discharge (about 11 days after admission)

Trial Locations

Locations (1)

The University of Texas Health Science Center at Houston

🇺🇸

Houston, Texas, United States

The University of Texas Health Science Center at Houston
🇺🇸Houston, Texas, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.